AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T18:19:07.881767Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
Wed 14 May 25, 11:00 AMLigand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Sun 11 May 25, 02:04 PMLigand Reports First Quarter 2025 Financial Results
Thu 08 May 25, 11:00 AMLigand to Participate in May Investor Conferences
Thu 01 May 25, 11:00 AMIs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?
Wed 30 Apr 25, 12:35 PMLigand to Report First Quarter 2025 Financial Results on May 8, 2025
Thu 24 Apr 25, 11:00 AMLigand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Thu 17 Apr 25, 10:00 AM3 Companies That May Be Trading Below Their Estimated Value
Wed 16 Oct 24, 01:02 PM| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Income before tax | 47.30M | -10.53800M | 796.64M | 173.33M | 57.23M |
| Minority interest | - | - | - | - | - |
| Net income | 37.46M | -2.98500M | 629.30M | 143.32M | 101.91M |
| Selling general administrative | 57.48M | 64.44M | 41.88M | 37.73M | 28.65M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 214.96M | 156.00M | 120.28M | 251.45M | 135.74M |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | 47.35M | 25.84M | 832.38M | - | - |
| Ebitda | 98.42M | 31.99M | 807.08M | 163.73M | 68.08M |
| Depreciation and amortization | 51.07M | 6.14M | - | - | - |
| Non operating income net other | - | -8.96300M | 25.31M | - | - |
| Operating income | 47.35M | 25.84M | 807.08M | 163.73M | 68.08M |
| Other operating expenses | 198.24M | 208.11M | 126.00M | 87.73M | 73.03M |
| Interest expense | -19.62600M | 27.42M | -35.74500M | -48.27600M | 11.40M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 9.84M | 7.55M | -167.33700M | -30.00900M | -44.67500M |
| Total revenue | 277.13M | 186.42M | 120.28M | 251.45M | 141.10M |
| Total operating expenses | 136.06M | 177.69M | 97.79M | 65.60M | 67.66M |
| Cost of revenue | 62.18M | 30.42M | 126.00M | - | 5.37M |
| Total other income expense net | -0.05400M | -36.38300M | -10.43700M | 9.60M | -10.84500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | -2.98500M | 629.30M | - | - |
| Net income applicable to common shares | - | -2.98500M | 629.30M | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 941.77M | 787.22M | 762.67M | 1297.59M | 1362.29M |
| Intangible assets | 266.65M | 366.90M | - | 551.04M | 595.33M |
| Earning assets | - | - | - | - | - |
| Other current assets | 22.90M | 3.84M | 3.40M | 10.86M | 6.04M |
| Total liab | 111.33M | 86.30M | 165.18M | 476.43M | 652.76M |
| Total stockholder equity | 830.44M | 700.91M | 597.49M | 821.16M | 709.52M |
| Deferred long term liab | - | - | - | - | 64.60M |
| Other current liab | 28.11M | 12.72M | 15.74M | 16.06M | 65.01M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | - | - | - | - | - |
| Retained earnings | 498.98M | 503.02M | 450.86M | 449.09M | 391.95M |
| Other liab | - | - | - | - | - |
| Good will | 105.25M | 103.37M | 105.67M | 181.21M | 189.66M |
| Other assets | - | - | - | - | - |
| Cash | 72.31M | 22.95M | 45.01M | 19.52M | 47.62M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 37.11M | 16.78M | 98.81M | 41.66M | 100.11M |
| Current deferred revenue | 1.28M | 1.22M | 0.35M | 11.00M | 29.43M |
| Net debt | -65.20200M | -16.78900M | 42.74M | 338.39M | -45.73400M |
| Short term debt | 1.29M | 0.41M | 77.41M | 6.21M | 1.89M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 7.11M | 6.17M | 87.75M | 357.91M | 1.89M |
| Other stockholder equity | 337.38M | 198.70M | 147.59M | 372.97M | 318.36M |
| Property plant equipment | - | - | - | - | 14.43M |
| Total current assets | 331.56M | 237.43M | 263.60M | 464.75M | 500.56M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | -86.44600M |
| Short term investments | 183.86M | 147.35M | 166.86M | 321.59M | 363.57M |
| Net receivables | 38.38M | 39.31M | 35.04M | 85.45M | 56.85M |
| Long term debt | - | - | - | - | 442.29M |
| Inventory | 14.11M | 23.97M | 13.29M | 27.33M | 26.49M |
| Accounts payable | 5.23M | 2.43M | 5.31M | 8.40M | 3.78M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -5.94200M | -0.81700M | -0.98400M | -0.91700M | -0.80100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | 391.95M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 202.53M | 5.92M | 4.74M | 29.06M | 55.41M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 610.22M | 549.79M | 499.07M | 832.84M | 861.73M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | 442.29M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | - | - | - | - | 615.67M |
| Change to liabilities | - | - | - | - | -4.58400M |
| Total cashflows from investing activities | - | - | - | - | 231.65M |
| Net borrowings | - | - | - | - | -222.20900M |
| Total cash from financing activities | 97.57M | -58.99800M | -275.99000M | -137.76100M | -310.54500M |
| Change to operating activities | - | - | - | - | - |
| Net income | -4.03200M | 53.82M | -5.21900M | 76.35M | -2.98500M |
| Change in cash | - | -22.05200M | 25.48M | -28.44000M | -24.31100M |
| Begin period cash flow | 22.95M | 45.01M | 19.52M | 47.96M | 72.27M |
| End period cash flow | - | 22.95M | 45.01M | 19.52M | 47.96M |
| Total cash from operating activities | 97.05M | 48.63M | 137.85M | 78.80M | 54.59M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 33.91M | 37.41M | 43.39M | 41.34M | 27.97M |
| Other cashflows from investing activities | -111.74900M | 0.42M | -0.86800M | -0.72600M | 25.32M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 9.62M | -10.87000M | 12.06M | -0.42700M | -17.79900M |
| Change to account receivables | -6.45900M | -4.38200M | 56.90M | -32.59200M | -16.91700M |
| Sale purchase of stock | - | - | - | -18.44600M | -77.99800M |
| Other cashflows from financing activities | 97.57M | -4.54700M | -18.42100M | -7.06800M | -3.80600M |
| Change to netincome | - | - | - | - | -1.82000M |
| Capital expenditures | 1.82M | 53.85M | 17.92M | 8.76M | 4.46M |
| Change receivables | - | - | - | - | -26.06100M |
| Cash flows other operating | - | - | - | - | 57.59M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | -24.31100M |
| Change in working capital | - | -34.40200M | 65.68M | -57.00400M | -10.06400M |
| Stock based compensation | 41.09M | -94.77800M | -21.17200M | 38.78M | 30.73M |
| Other non cash items | 26.08M | -19.89600M | 34.45M | 139.61M | 150.62M |
| Free cash flow | 95.23M | -5.22100M | 119.93M | 70.04M | 50.13M |
Sector: Industry:
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| LGNXZ Ligand Pharms Glucagon |
- -% | - | - | - | - | - | ||
| DOGEF Orsted A/S |
-1.046 4.02% | 25.00 | 28.82 | 0.66 | 6.50 | 0.07 | 3.88 | 15.58 |
| NCRRP NCR Corp Pref A |
- -% | 1002.00 | 1034.35 | - | - | - | ||
| TBB AT&T Inc. 5.35% GLB NTS 66 |
- -% | 20.76 | 4.60 | - | - | - | ||
| CCZ Comcast Holdings Corp |
0.21 0.32% | 65.15 | 55.07 | - | - | - |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
555 Heritage Drive, Jupiter, FL, United States, 33458
| Name | Title | Year Born |
|---|---|---|
| Mr. Todd C. Davis Ph.D. | CEO & Director | 1961 |
| Mr. Octavio Espinoza | Chief Financial Officer | 1971 |
| Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary | 1975 |
| Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development | NA |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology & Scientific Affairs | NA |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations & QA - Capitsol | 1969 |
| Mr. Patrick Lucy | Senior VP & CBO Protein Expression Business | NA |
| Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy | 1951 |
| Mr. Richard B. Baxter | Senior VP of Investment Operation | NA |
| Mr. Scott M. Plesha | CEO of Pelthos Therapeutics | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...